Table 2.
Study treatment and post-discontinuation therapy based on the PRONOUNCE trial (US and Japan models) [15]
| Agents used in model | Dose (mean, mg) | Dose (SE) |
|---|---|---|
| Systematic therapy | ||
| Pemetrexed | 861.0 | 11.15 |
| Docetaxel | 112.5 | 11.25 |
| Paclitaxel | 340.5 | 5.40 |
| Carboplatin (with PemC) | 637.2 | 12.30 |
| Carboplatin (with PCB) | 628.2 | 12.97 |
| Bevacizumab | 1038.0 | 22.17 |
| Erlotinib (daily dose) | 150.0 | 15.00 |
| ESA utilization | PemC (%) | PCB (%) |
|---|---|---|
| Supportive care | ||
| Procrit | 5.8 | 3.6 |
| Epogen | 0.6 | 0.0 |
| Aranesp | 15.8 | 3.6 |
| G-CSF utilization | 15.8 | 26.5 |
| Transfusions | ||
| Fresh frozen plasma | 0.6 | 0.0 |
| Packed red blood cells | 34.5 | 11.4 |
| Platelets | 5.8 | 4.2 |
| Post-discontinuation therapy | ||
| Pemetrexed | 8.8 | 34.1 |
| Docetaxel | 26.4 | 6.1 |
| Paclitaxel | 6.0 | 7.3 |
| Carboplatin | 9.9 | 16.2 |
| Bevacizumab | 7.7 | 12.8 |
| Erlotinib | 9.3 | 7.8 |
ESA Erythropoiesis-stimulating agent, G-CSF Growth colony stimulating factor, PCB Induction bevacizumab plus paclitaxel plus carboplatin followed by single-agent bevacizumab, PemC Induction pemetrexed plus carboplatin followed by single-agent pemetrexed, SE Standard error